Nishizawa Y - Search Results

1

Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on hemodialysis: preliminary report.

Nishizawa Y, Morii H, Ogura Y, De Luca HF. Nishizawa Y, et al. Contrib Nephrol. 1991;90:196-203. doi: 10.1159/000420143. Contrib Nephrol. 1991. PMID: 1659967 Clinical Trial.

2

Biological activities of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 on human promyelocytic leukemic HL-60 cells: effects of fetal bovine serum and of incubation time.

Okuno S, Inaba M, Nishizawa Y, Morii H. Okuno S, et al. Among authors: nishizawa y. Miner Electrolyte Metab. 1995;21(1-3):211-6. Miner Electrolyte Metab. 1995. PMID: 7565452

3

Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.

Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H. Nishizawa Y, et al. Clin Nephrol. 1995 Apr;43(4):268-77. Clin Nephrol. 1995. PMID: 7606882 Clinical Trial.

4

Impaired homologous upregulation of vitamin D receptor in rats with chronic renal failure.

Koyama H, Nishizawa Y, Inaba M, Hino M, Prahl JM, DeLuca HF, Morii H. Koyama H, et al. Among authors: nishizawa y. Am J Physiol. 1994 May;266(5 Pt 2):F706-12. doi: 10.1152/ajprenal.1994.266.5.F706. Am J Physiol. 1994. PMID: 8203553

5

Effect of uremic serum on 1,25-dihydroxyvitamin D3-induced differentiation of human promyelocytic leukemia cell, HL-60.

Inaba M, Okuno S, Koyama H, Ishimura E, Nishizawa Y, Morii H. Inaba M, et al. Among authors: nishizawa y. Nephron. 1993;63(2):152-8. doi: 10.1159/000187174. Nephron. 1993. PMID: 8383808

6

Effect of substituting fluorine for hydrogen at C-26 and C-27 on the side chain of 1,25-dihydroxyvitamin D3.

Inaba M, Okuno S, Nishizawa Y, Imanishi Y, Katsumata T, Sugata I, Morii H. Inaba M, et al. Among authors: nishizawa y. Biochem Pharmacol. 1993 Jun 9;45(11):2331-6. doi: 10.1016/0006-2952(93)90207-d. Biochem Pharmacol. 1993. PMID: 8517874

7

The effect of oral 1 alpha-hydroxycalciferol treatment on bone mineral density in hemodialysis patients.

Morita A, Tabata T, Inoue T, Nishizawa Y, Morii H. Morita A, et al. Among authors: nishizawa y. Clin Nephrol. 1996 Dec;46(6):389-93. Clin Nephrol. 1996. PMID: 8982555

8

1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide.

Jono S, Nishizawa Y, Shioi A, Morii H. Jono S, et al. Among authors: nishizawa y. Circulation. 1998 Sep 29;98(13):1302-6. doi: 10.1161/01.cir.98.13.1302. Circulation. 1998. PMID: 9751679

9

Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells.

Imanishi Y, Inaba M, Seki H, Koyama H, Nishizawa Y, Morii H, Otani S. Imanishi Y, et al. Among authors: nishizawa y. J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):243-8. doi: 10.1016/s0960-0760(99)00112-0. J Steroid Biochem Mol Biol. 1999. PMID: 10622414

10

Dibutyryl cAMP enhances the effect of 1,25-dihydroxyvitamin D3 on a human promyelocytic leukemia cell, HL-60, at both the receptor and the postreceptor steps.

Inaba M, Okuno S, Koyama H, Nishizawa Y, Morii H. Inaba M, et al. Among authors: nishizawa y. Arch Biochem Biophys. 1992 Feb 14;293(1):181-6. doi: 10.1016/0003-9861(92)90382-7. Arch Biochem Biophys. 1992. PMID: 1309983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,358 results

Search Page

Filters